In sum, these studies provide the first insights into YWHAE-NUTM2 oncogenic mechanisms and intriguingly show that YWHAE-NUTM2 dysregulates both RAF1/BRAF and the Hippo pathway to cause overexpression of cyclin D1 (Fig. 8), which is a key diagnostic biomarker in HG-ESS. This evidence concerns the gene BRAF and endometrioid stromal sarcoma.